HighTower Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

HighTower Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$652K	Buy	26,333 +2,489	+10%	+$59.3K	﹤0.01%	2498
2025 Q4	$557K	Buy	23,844 +9,238	+63%	+$206K	﹤0.01%	2527
2025 Q3	$288K	Buy	+14,606	New	+$300K	﹤0.01%	3081
2025 Q2	–	Sell	-81,340	Closed	-$1.97M	–	3794
2025 Q1	$1.97M	Buy	+81,340	New	+$1.83M	﹤0.01%	1532
2021 Q3	–	Sell	-22,751	Closed	-$132K	–	3227
2021 Q2	$132K	Buy	+22,751	New	+$117K	﹤0.01%	2752
2020 Q3	–	Sell	-11,042	Closed	-$50K	–	2570
2020 Q2	$50K	Hold	11,042	–	–	﹤0.01%	2197
2020 Q1	$43K	Buy	11,042 +131	+1%	+$538	﹤0.01%	2023
2019 Q4	$42K	Buy	10,911 +500	+5%	+$2.34K	﹤0.01%	2132
2019 Q3	$56K	Buy	+10,411	New	+$55.5K	﹤0.01%	2213
2018 Q4	–	Sell	-12,411	Closed	-$47K	–	2229
2018 Q3	$47K	Hold	12,411	–	–	﹤0.01%	2127
2018 Q2	$38K	Buy	12,411 +1,000	+9%	+$3.03K	﹤0.01%	2081
2018 Q1	$28K	Buy	11,411 +1,000	+10%	+$3.32K	﹤0.01%	2052
2017 Q4	$41K	Buy	+10,411	New	+$34.4K	﹤0.01%	2117

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

HighTower Advisors's CPRX Position: Q1 2026 in Review

HighTower Advisors increased its Catalyst Pharmaceutical (CPRX) stake by 10% in Q1 2026, buying an estimated $59.3K and bringing the position to 26,333 shares worth $652K. The position accounts for ﹤0.01% of the portfolio, ranked #2498.

HighTower Advisors first reported a position in CPRX in Q4 2017 and has held it in 13 quarters since. The position peaked at $1.97M in Q1 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

HighTower Advisors held 26,333 shares of Catalyst Pharmaceutical worth $652K as of Q1 2026.
HighTower Advisors bought 2,489 Catalyst Pharmaceutical shares in Q1 2026, an estimated $59.3K.
Catalyst Pharmaceutical made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #2498 holding.
HighTower Advisors first reported a position in Catalyst Pharmaceutical in Q4 2017 and has held it in 13 quarters since.
HighTower Advisors's Catalyst Pharmaceutical position peaked at $1.97M in Q1 2025.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.